Curriculum · Gynecology / Women's Health / Infertility / Perinatal Care / Birth Spacing
Depot medroxyprogesterone acetate
What it is
Medroxyprogesterone acetate is also known as depot medroxyprogesterone acetate in injectable form, and the same agent is written as DMPA and sold as Depo Provera. It is one of the two progesterone only types, the other being the mini pills taken by mouth. Progestins act by causing atrophy and decidualization of endometrial tissues; progesterone thickens the cervical mucosa so that migration is inhibited, and thins the endometrial lining so that implantation is inhibited. The dose is given as once every 3 months, and in the endometriosis table as 150 mg IM/13 wk or 104 mg SC/12-14 wk. Unlike the combined pill it does not depend on gut flora for absorption, so it is not affected by Abs.
How it is treated
DMPA is used when estrogen is contraindicated, and it carries no DVT risk because it holds no estrogen. It is safe in breast feed and improves milk quality. Outside contraception it is listed for menorrhagia, dysmenorrhea, endometriosis, endometrial ca and acute SCD crisis. In primary dysmenorrhea it sits with the other hormonal options: COCP 3 weeks on and 1 week off, progestin only pills, Mirena, depot medroxyprogesterone acetate injections every 3 months, and the progestin releasing implanted rods Implanon and Nexplanon. Among the first-line agents for endometriosis-associated pain it is grouped with the other progestins, the LNG-IUS and norethindrone 5-20 mg po daily, all of which cause atrophy and decidualization of endometrial tissues. The injectable dose is set out as 150 mg IM 3 monthly, with the injection taken within 5 days of the cycle, and a back up method used for 7 days if it is not given in the first 5 days of the period. Its mechanism there is to thicken the cervical mucous, inhibit ovulation, slow tubal motility and thin the endometrium. It is indicated in breastfeeding from 6 wks postpartum, in epilepsy, in sickle cell, and in the obese patient and the patient on anticoagulant, and its advantages are a lower risk of ectopic pregnancy, of functional ovarian cysts and of endometrial cancer.
Depot medroxyprogesterone also appears among the drugs for the medical management of chronic abnormal uterine bleeding, at 150 mg intramuscularly or 104 mg subcutaneously every 13 weeks.
What can go wrong
The failure of Provera is 3%. The side effects listed are irregular bleed at the beginning, weight gain, breast tenderness, mood swing and a low HDL. There is a delay in the return of fertility, and that delay is what separates the injection from the progesterone implant, where return is rapid. Two numbers are given for it: one page puts the return of ovulation at around 10 months, and the contraception table gives the delay as max 18 months, which is the outer limit to quote. The spotting and irregular vaginal bleeding decrease with each injection, and osteoporosis is listed among the side effects in its own right. The contraindications on that table are those of the implant, breast cancer, SLE, antiphospholipid syndrome, hepatocellular adenoma and migraine with aura, with DM with vascular disease, CVD and HTN named beside them. The endometriosis table adds acne, depression, menstrual irregularities, hirsutism and decreased BMD, which is bone mineral density, with a note not to use it >2 y. Breast cancer in the last 5 yrs is the absolute contraindication for progesterone only methods. One point is stated in the negative and is worth holding: thromboembolic disease is not a side effect of Depo-Provera.
Unscheduled bleeding is a common initial adverse effect of it, but one-half of patients become amenorrheic after 12 months of use.